10 May 2017 10:09
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Director/PDMR Shareholding
The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that it has made the following purchases of ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") (the "Purchases"):
Date | Ordinary Shares purchased | Price paid per Ordinary Share (p) |
5th May 2017 | 1,117 | 4.8 |
8th May 2017 | 100,000 | 5.0 |
9th May 2017 | 100,000 | 5.0 |
Following the Purchases Vulpes has a total direct and indirect interest in 54,346,401 equivalent to 18.44% of Proteome Sciences' total issued share capital.
The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 54,346,401 Ordinary Shares of the Company representing 18.44% of the issued share capital of the Company.
1. | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Vulpes Life Sciences Fund |
2. | Reason for the Notification | |
a) | Position/status | PCA of Martin Diggle (NED) |
b) | Initial notification/Amendment | Initial notification |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Proteome Sciences plc |
b) | LEI | n/a |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the Financial instrument, type of instrument | Ordinary Shares of 1p each |
Identification code | GB0003104196 | |
b) | Nature of the transaction | Purchase |
c) | Price(s) and volume(s) | 1,117 Ordinary Shares at 4.8p per Ordinary Shares 100,000 Ordinary Shares of 5.0p per Ordinary Shares 100,000 Ordinary Shares at 5.0p per Ordinary Shares |
d) | Aggregated information: · Aggregated volume · Price |
201,117 Ordinary Shares of 1p each purchased at a volume weighted average price of 5.00p per Ordinary Share |
e) | Date of the transaction | 5 May 2017 (First Purchase), 8 May 2017 (Second Purchase), 9 May 2017 (Third Purchase) |
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) |
For further information: Proteome Sciences plc | |
Dr Jeremy Haigh, Chief Executive Officer Tel: +44 (0)1932 865065 | |
Dr Ian Pike, Chief Scientific Officer | |
Geoff Ellis, Finance Director | |
finnCap Limited (Nominated Adviser/Broker) |
|
Geoff Nash/James Thompson | Tel: +44 (0)20 7220 0500 |
Tony Quirke (broking) IFC Advisory (Financial PR and IR) | |
Tim Metcalfe/Graham Herring/Miles Nolan | Tel: +44 (0)20 3053 8671 |
| |
Notes for editors:
Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®, TMTcalibrator™) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in Cobham, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.
Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.
Proteome (PRM)